CLAIM #43711 · Morgan Stanley (MS) · 2021Q4 earnings call · Jan 19, 2022 · due Dec 31, 2022
“I don't think 10% or 11% is realistic to hold. But certainly, we're not going back to anywhere near where we were in the old days.”
James Gorman · CEO
In context
“bring in the deposits and what we've done with the bank and the online banking. And then you throw on top of that E*TRADE and what that's been doing in growth. And so Christian, it's an interesting story. It's many, many parts, which is why we're confident it's going to keep going. Just recruiting, that's different. You turn that spigot on or off, but it's not just recruiting. So I think there's going to be strong organic growth. I mean these numbers, we said unprecedented for reason. It had never -- we've never seen -- it's 10%, 11% organic growth year-over-year. That's got to be the best in the industry, and overwhelmingly, the best in our history. And it's better than, frankly, many of the traditional faster-growing, so-called faster-growing companies. So we're really excited about it. I don't think 10% or 11% is realistic to hold. But certainly, we're not going back to anywhere near where we were in the old days. Sharon Yeshaya: If I can also add to it, Christian, I would just say if you actually look at the data, is relatively, as James said, balanced across many of these different sectors. But as you think of just the advisor channel, you're seeing not only -- we've, I think, spent a lot of time speaking to the community around assets held away. We are seeing existing clients bringing assets as well as new clients bringing assets to the advisor-led channel. So you are seeing a balance of both. Christian Bolu : Okay. Thank you. For my second question, on expenses, really nice control in the quarter, but all your peers are speaking about elevated expense growth going forward to retain talent and just to invest for growth. Can you talk about just longer-term, how you're thinking about balancing sor”
Verify independently
SEC filings for MS ↗ · Claim quote is verbatim from the 2021Q4 earnings call.